William Blair analyst Sarah Schram has maintained their bullish stance on BHVN stock, giving a Buy rating yesterday.
Sarah Schram’s rating is based on the promising results from Biohaven Ltd.’s clinical trials, particularly the impressive performance of BHV-1300. The drug achieved a median 80% reduction in IgG levels with weekly subcutaneous dosing, surpassing expectations and outperforming similar therapies from competitors. This significant reduction highlights the potential of BHV-1300 in treating conditions related to high IgG levels, such as myasthenia gravis, and positions Biohaven as a strong contender in the market.
Moreover, the safety profile of BHV-1300 is encouraging, with no clinically significant adverse events reported during the trials. The company’s strategic plans to advance their second IgG degrader, BHV-1310, into clinical trials further strengthen their pipeline. These factors collectively contribute to Sarah Schram’s Buy rating for Biohaven Ltd., indicating confidence in the company’s future growth and development prospects.
In another report released yesterday, Piper Sandler also reiterated a Buy rating on the stock with a $76.00 price target.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BHVN in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com